收起

掌上阜外
官方微信
官方微博
我要挂号
意见信箱
我要求职
我要进修
志愿服务
返回顶部
  • 人才队伍
  • 国家高层次人才

王淼

发布时间:2021-11-04 16:01:04

王淼 博士 研究员 博士生导师

血管生物学与药理学课题组组长

Miao Wang Ph.D., FAHA

Professor of Pharmacology

Laboratory of Vascular Biology and Pharmacology

E-mail: miao.wang at pumc.edu.cn

个人简介:
王淼博士1996年毕业于浙江大学生物科学与技术系,1999年于浙江大学获得动物生理生化方向硕士学位,2002年于北京协和医学院获得免疫学方向博士学位。在美国宾夕法尼亚大学(University of Pennsylvania)药理系从事博士后研究,获得美国宾夕法尼亚大学医学院临床研究认证( 临床流行病学与生物统计学)。 2006年起先后担任宾西法尼亚大学药理系做研究助理(Research Associate)和研究助理教授(Research Assistant Professor)。 2010起受聘为美国辉瑞制药全球研发(Pfizer Global R&D) 心血管与代谢性疾病研发部主要科学家(Principal Scientist)。2013年就职于中国医学科学院/北京协和医学院国家心脏病中心心血管疾病国家重点实验室。长期从事心血管疾病炎症调控机制与药物发现研究。

美国心脏协会(AHA)资深会员(FAHA),美国动脉硬化血栓与血管生物学(ATVB)科学年会组委会委员,美中医药开发协会(SAPA)终身会员(2009-2010 SAPA-GP常务理事),中国老年学和老年医学学会老年病学分会常务委员,中国生理学会血栓与止血专业委员会委员,2019年获“药明康德”生命化学研究奖。

主要研究方向是心血管疾病炎症免疫调节机制与新药发现。发表主要论文于Nature Communications、PNAS、Circulation(2008, 2011, 2017)、J Clin Invest、ATVB(2018a, 2018b, 2019, 2020)等学术期刊。主编《冠心病:治疗与药物发现》英文书(Springer出版社, 2020)

Education Background & Professional Experience:
Dr. Wang is a Professor and Head of Laboratory of Vascular Biology and Pharmacology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC). He got a Bachelor degree and a Master degree from Zhejiang University, and obtained a Ph.D. from CAMS & PUMC in 2002. Dr. Wang completed postdoctoral research and obtained a Clinical Research Certificate in Clinical Epidemiology & Biostatistics, at University of Pennsylvania, and then joined the faculty of the Department of Pharmacology, as Research Associate and Research Assistant Professor from 2006-2010.

Besides his academic experience, Dr. Wang had been working in the Cardiovascular and Metabolic Disease Research Unit at Pfizer, as Principal Scientist, since 2010 until he took the current position in 2013.

Dr. Wang serves in the program committee of Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Scientific Sessions, American Heart Association (AHA). He is fellow of AHA (FAHA), a lifetime member of Chinese American Academy of Cardiology (CAAC) and of Sino-American Pharmaceutical Professionals Association (SAPA, also as an executive committee member, SAPA-GP, 2009-2010).

Dr. Wang’s research aims to elucidate the mechanisms of coronary heart disease, with a particular focus on inflammation and thrombosis, and to translate novel mechanistic insights into therapeutic innovation. He has representative publications in Nat Commun, PNAS, J Clin Invest, Circulation (2008, 2011, 2017), ATVB (2018a, 2018b, 2019, 2020). He is chief editor of the book “Coronary Artery Disease: Therapeutics and Drug Discovery”. 2020 Springer Press.

研究领域:围绕疾病防治的临床需要,运用分子细胞生物学、遗传学和影像学手段,整合疾病动物模型研究与临床研究,探索心血管疾病炎症调控机制,并探索其可能的临床应用。目前研究集中于(1)冠状动脉粥样硬化与血栓的炎症调节机制;(2)新药靶的功能鉴定与新药发现。

Research Interests:
The laboratory aims to elucidate the mechanisms by which inflammation regulates cardiovascular disease, by integrating molecular, cellular, genetic, and imaging approaches with animal model and clinical research, and to translate such novel mechanistic insights into therapeutic innovation. Our current research is focused on (1) coronary atherosclerosis and thrombosis, with a particular interest in the role of prostanoids (a group of bioactive lipids derived from membrane phospholipids, also suppressed by nonsteroidal anti-inflammatory drugs) and the signaling transduction of endothelial cell interactions with blood cells; (2) validation and therapeutic exploration of novel cardiovascular drug targets, through worldwide collaboration with academia and pharmaceutical industry. Taking advantages of the on-campus translational facilities of the National Center for Cardiovascular Diseases, including Large Animal Research Center and the National Clinical Research Center, the lab is actively pursuing mechanism-based therapeutic discovery.

代表性的SCI论文 / Selected Publications:

1) Hao H, Ma X, Chen H, Zhu L, Xu Z, Li Q, Xu C, Zhang Y, Peng Z, Wang M*(*Corresponding author). The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice. J Cell Mol Med. 2020;24(17):9638-9645

2) Zhu L, Zhang Y, Guo Z, Wang M * (*Corresponding author). Cardiovascular Biology of Prostanoids and Drug Discovery. Arterioscler Thromb Vasc Biol. 2020;40(6):1454-1463. (Invited review)

3) Wan Q, Qian S, Huang Y, Zhang Y, Peng Z, Li Q, Shu B, Zhu L, Wang M* (*Corresponding author). Drug Discovery for Coronary Artery Disease. Adv Exp Med Biol. 2020;1177:297-339.

4) Peng Z, Shu B, Zhang Y, Wang M * (*Corresponding author). Endothelial Response to Pathophysiological Stress. Arterioscler Thromb Vasc Biol. 2019;39(11):e233-e243. (Invited review)

5) Zhu L, Xu C, Huo X, Hao H, Wan Q, Chen H, Zhang X, Breyer RM, Huang Y, Cao X, Liu D-P, FitzGerald GA, Wang M*(*Corresponding author). The Cyclooxygenase-1/mPGES-1/Endothelial Prostaglandin EP4 Receptor Pathway Constrains Myocardial Ischemia-Reperfusion Injury. Nature Communications. 2019. DOI: 10.1038/s41467-019-09492-4.

6) Wang M* (*Corresponding author), Hao H, Leeper NJ, Zhu L. Thrombotic Regulation From the Endothelial Cell Perspectives. Arterioscler Thromb Vasc Biol. 2018;38(6):e90-e95.

7) Hao H, Hu S, Wan Q, Xu C, Chen H, Zhu L, Xu Z, Meng J, Breyer RM, Li N, Liu DP, FitzGerald GA, Wang M* (*Corresponding author). Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury. Arterioscler Thromb Vasc Biol. 2018;38(5):1115-1124.

8) Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, Chu F, Huo X, Tang Y, Sun X, Ding B, Liu D, Hu S, Wang M* (*Corresponding author). Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017; 135(13):1253-1264.

9) Wang M* (*Corresponding author), Jin W, Guo AM, Stubbe J. Cardiovascular Inflammation. Mediators of Inflammation. 2013, 11:101. doi: 10.1155/2013/123513.

10) Knight DR, Smith AH, Schroeder RL, Huang C, Beebe DA, Sokolowski SA, Wang M* (*Corresponding author). Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery. Journal of Translational Medicine. 2013, 11:101 doi:10.1186/1479-5876-11-101

11) Lowell AN, Qiao H, Liu T, Ishikawa T, Zhang H, Oriana S, Wang M, Ricciotti E, FitzGerald GA, Zhou R, and Yamakoshi Y. Functionalized Low-Density Lipoprotein Nanoparticles for in Vivo Enhancement of Atherosclerosis on Magnetic Resonance Images. Bioconjugate Chem. 2012; 23(11):2313-9.

12) Wang M* (*Corresponding author), Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, Grant G, Cheng Y, Lawson JA, Assoian RK, Jones PL, Fitzgerald GA*. Microsomal Prostaglandin E2 Synthase-1 Modulates the Response to Vascular Injury. Circulation. 2011;123(6):631-9.

13) Hui Y, Crichton I, Ricciotti E, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA. Targeted Deletions of COX-2 and Atherogenesis in Mice. Circulation. 2010;121(24):2654-60

14) Wang M* (*Corresponding author), Jiang M, Cooper PR, Zhao H, Hui Y, Yao Y, Tate JC, Damera G, Lawson JA., Jester WF, Panettieri RA and FitzGerald GA. Deletion of microsomal Prostaglandin E Synthase does not alter ozone-induced airway hyper-responsiveness. J Pharmacol Exp Ther. 2010;334(1):63-8

15) Damera G, Zhao H, Wang M, Smith M, Kirby C, Jester WF, Lawson JA, Panettieri RA Jr. Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009;296(4):L674-83.

16) Wang Y, Barthold J, Figueroa E, González R, Noh PH, Wang M, Manson J. Analysis of five single nucleotide polymorphisms in the ESR1 gene in cryptorchidism. Birth Defects Res A Clin Mol Teratol. 2008;82(6):482-5

17) Wang M, Lee E, Song W-L, Ricciotti E, Rader DJ, Lawson JA, Puré E and FitzGerald GA.  Microsomal PGE Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II Induced Abdominal Aortic Aneurysm Formation. Circulation, 2008;117(10):1302-9.

18) Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA. Tetranor PGDM: An abundant urinary metabolite reflects biosynthesis of PGD2 in mice and humans. J Biol Chem. 2008;283(2):1179-88.

19) Song WL, Lawson JA, Wang M, Zou H, FitzGerald GA. Noninvasive Assessment of the Role of Cyclooxygenases in Cardiovascular Health: A Detailed HPLC/MS/MS Method. Methods in Enzymol. 2007;433:51-72.

20) Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E and FitzGerald GA. Deletion of microsomal PGE synthase -1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006; 103(39):14507-12.

21) Cheng Y, Wang M (co-first authorship), Yu Y, Lawson JA, Funk CD and FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116(5):1391-9.

22) Wang D, Wang M, Cheng Y, FitzGerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol. 2005, 5(2):204-10.

23) Egan KM, Wang M, Lucitt MB, Zukas AM, Puré E, Lawson JA and FitzGerald GA. Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism. Circulation, 2005, 111(3): 334-342


上一篇: 没有了!

下一篇: 鲁向锋